Medical reviewer
Victor Bjork
Uppsala University · Molecular Biology - Longevity Biotech
- Institution
- Uppsala University
- Current role
- Business Development Professional | Longevity Biotech
- Credential
- MA, Molecular Biology
- Verified profile
About
Victor Bjork has a long-term passion for improving the human condition, and age-related disease — a major global challenge — is a cause he cares deeply about.
Originally from Sweden, where he studied molecular biology, Victor brings extensive international experience: he has lived and studied in Belgium and worked at several biotech companies in California, New York and Switzerland, in roles ranging from benchwork to biotech business development.
He is a director of the Belgian NGO Heales, which works on age-related diseases. Among his contributions there is the establishment of the Eurosymposium on Healthy Ageing conference series.
Conflict-of-interest disclosure
Victor works as an independent longevity consultant, and some of his clients are companies in the same field this site covers. He checks our articles for scientific accuracy — nothing more. He doesn't choose what we write about, doesn't recommend products, and has no stake in any commercial deals we make.
Review process
- Every peptide profile and research summary on this site is reviewed for scientific and pharmacological accuracy before publication.
- Review covers mechanism-of-action claims, dosing figures, drug-interaction considerations, regulatory and legal status framing, and whether the strength of the underlying evidence is represented honestly — a single mouse study and a phase III trial don’t get described the same way.
- Cited references are spot-checked against PubMed to confirm the study exists, the PMID is correct, and the paper supports the claim we’ve attached to it.
- The reviewer has no role in editorial selection, product recommendations, or commercial relationships.
Reviewed by Victor Bjork
May 12, 2026
TB-500 for Tendon Recovery: What the Evidence Shows
A deep-dive into TB-500's evidence base for tendon recovery, covering preclinical data, proposed mechanisms, published dosing protocols, and where it stands vs. alternatives.
May 12, 2026
BPC-157 Oral Bioavailability: Myth vs. Evidence
The claim that BPC-157 is orally bioavailable circulates widely in peptide forums. Here is what the actual literature supports and where the myth breaks down.
Jun 12, 2026
TB-500 vs BPC-157: Which Has the Better Evidence
TB-500 and BPC-157 compared on efficacy, safety, and practical use. See which peptide has stronger evidence for tissue repair and recovery decisions.
The Evidence-Based Peptide Library
Independent research summaries on the peptides everyone's talking about — from GHK-Cu to BPC-157 — verified by scientists and stripped of the marketing spin.
See full directory